Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Group Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
Guided by innovation and internationalization, the company continuously enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.
Fosun Pharma has incorporated sustainable development into the Group's overall development strategy, emphasizing long-term ESG governance capabilities, and established a three-level ESG governance structure supervised by the board of directors (the “Board”), implemented by the ESG Committee, and executed by the ESG Working Group. The ESG Committee of the Board is responsible for formulating and promoting the Group's ESG vision, goals, and strategies, and provides advice to the Board; the ESG Working Group is responsible for sorting out key ESG issues, formulating sustainable development quantitative targets, and tracking progress. The ESG Committee and the ESG Working Group are committed to integrating ESG concepts into corporate operations and enhancing the company's sustainability.
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Group Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
We are looking for people that recognize and practice our cultural values, and can learn fast to create continuous value; possess profound professional knowledge of the industry, a wide vision of different regions, and global-level expertise in a certain field. We will also be committed to cultivating international top talent with outstanding performance and great potential.
Common Name:Dihydroartemisinin and Piperaquine Phosphate Tablets
It is a compound preparation composed of dihydroartemisinin and piperaquine phosphate, and passed the WHO prequalification in 2019. Therapeutic Area: treatment of uncomplicated malaria.
Common Name:Sulfadoxine/Pyrimethamine + Amodiaquine (Hydrochloride) Dispersible Tablets
This product passed the WHO prequalification in 2018 and is the world's first drug for malaria prophylaxis in children approved for seasonal malaria chemoprevention (SMC). Therapeutic Area: prophylaxis for malaria.
It is a global initiative and the "gold standard" for treatment of severe malaria. It passed the WHO prequalification in 2005, is the first-choice drug for severe malaria recommended by the WHO, and is known as an "anti-malarial miracle drug". Therapeutic Area: treatment of severe malaria
First-line anti-TB drug indicated for the treatment of tuberculosis in combination with other anti-TB drugs (such as streptomycin, isoniazid, rifampicin and ethambutol). a product passed consistency evaluation.
First-line anti-tuberculosis drug indicated for the treatment of tuberculosis caused by mycobacterium tuberculosis in combination with other anti-tuberculosis drugs; also used for the treatment of tuberculous meningitis and atypical mycobacterial infections; a product passed consistency evaluation.
First-line antituberculosis drug indicated for the treatment of various types of TB, including tuberculous meningitis and other mycobacterium tuberculosis infections. The first isoniazid product passed consistency evaluation.
Second-line antituberculous drug and the essential therapeutic drug for treatment of drug-resistant tuberculosis by inhibiting the cell wall synthesis of mycobacterium tuberculosis; a required drug for short-course regimen for treatment of drug-resistant tuberculosis.
First-line drug for treatment of drug-susceptible tuberculosis; 0.3 g in strength, reduced number of tablets taken by patients and improved compliance; a product passed consistency evaluation.
First-line drug for treatment of drug-susceptible tuberculosis; rifampicin with less hepatic impairment and higher bioavailability; achieving the therapeutic effect of 0.6 g of general rifampicin with only two capsules per time.
A drug recommended by WHO guidelines in standard treatment regimens for drug-susceptible tuberculosis; improved patient compliance; reduced drug resistance rate.
Common Name:Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid Tablets (II)
A drug recommended by WHO guidelines in standard treatment regimens for drug-susceptible tuberculosis; the only fixed-dose four-drug combination for tuberculosis treatment included in the WHO Model Lists of Essential Medicines; improved patient compliance; reduced drug resistance rate.
It has quality of brand name drug, and is a product under National Medical Insurance Class B; a confidence choice for monotherapy of mixed infection of aerobic bacteria and anaerobic bacteria; simple choice for prevention of surgical infection and perioperative infection; economical choice for empirical therapy of infection of ESBLs-producing bacteria.
It has quality of brand name drug, and is a product under National Medical Insurance Class B; it is recommended by many guidelines and consensus at home and abroad; it has a broad antibacterial spectrum, covering G+ bacteria, G-bacteria and anaerobic bacteria; it has good stability against ESBL enzymes, and has a low drug resistance rate clinically.
It is an original product under National Medical Insurance Class B; it is the first oral anti-HBV drug marketed in China; it has high safety, has strong antiviral ability, and is a classic drug for patients with chronic hepatitis B; long-term treatment with it can effectively improve liver tissue inflammation and delay the progress of chronic hepatitis B disease.
It is a China's national essential drug under National Medical Insurance Class A, and is included in the National Centralized Drug Procurement List; it is recommended by multiple guidelines at home and abroad; it is an antibacterial drug for unrestricted use, and an experience choice for treatment of various common infections.